Sanna Bastiano 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Apr 14, 2023
Insider Transaction Report
Form 4
Sanna Bastiano
EVP, Cell & Genetic Therapies
Transactions
- Sale
Common Stock
2023-04-12$325.70/sh−874$284,662→ 46,406 total - Sale
Common Stock
2023-04-12$326.45/sh−4,068$1,327,999→ 42,338 total - Sale
Common Stock
2023-04-12$327.43/sh−2,625$859,504→ 39,713 total
Footnotes (5)
- [F1]Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.
- [F2]Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $325.70 (range $325.00 to $325.98).
- [F4]Open market sales reported on this line occurred at a weighted average price of $326.45 (range $326.00 to $326.99).
- [F5]Open market sales reported on this line occurred at a weighted average price of $327.43 (range $327.01 to $327.91).